CA-MFA
9.9.2021 16:45:08 CEST | Business Wire | Press release
MFA , an international organization championing the global industry adoption of private networks, is gaining industry momentum with the recent certification of the Nokia Industrial MulteFire fieldrouter 700 and announcement of Uni5G Technology Blueprints. The Nokia MulteFire solution , which is available for deployment with Nokia Digital Automation Cloud, will enable MulteFire LTE-based private network adoption worldwide, unlocking access to unlicensed spectrum. With deployment available globally, it can be used by small and medium enterprises without access to licensed spectrum and it can bring additional capacity as a complementary layer to wireless networks and enable new nomadic use cases to advance Industry 4.0.
In addition to supporting 4.9G/LTE private networks, MFA recently announced its expansion to 5G with Uni5G Technology Blueprints, which help provide guidance to enterprises looking to deploy 5G private networks. MFA is also developing best practices and targeted guides to help industry verticals implement the key 3GPP 5G specification features that are relevant to their specific deployment.
The MFA Certification Program ensures that devices have implemented the MulteFire specifications correctly and are able to interoperate with devices from other manufacturers.
“The Nokia MulteFire solution has passed rigorous interoperability testing at our Authorized Test Lab DEKRA,” said Scott Fischel, MFA Certification Group Chair. “We congratulate Nokia on delivering the world’s first MulteFire Certified end-to-end solution that will provide end-users with confidence that it can meet the robust connectivity requirements offered by MulteFire 4.9G/LTE private wireless.”
“Private 5G and LTE networks are a rapidly growing market and will account for over $5B in global enterprise expenditure by 2025,” said Pablo Tomasi, Principal Analyst, Private Networks, Omdia. “MFA aims to support and accelerate the private 5G networks market through both this certification program and by tackling the issue of replicability and complexity through the delivery of Uni5G Technology Blueprints developed to simplify deployment for different industry verticals.”
The MFA Certification Program is available to MFA members, and it will help facilitate further expansion of the MulteFire private wireless ecosystem. For companies interested in joining the MFA, visit www.mfa-tech.org/become-a-member .
Resources:
- Interview: Meet MFA Certificate Authority
- Interview: Meet MFA Authorized Test Lab – DEKRA
- Video: Uni5G and MulteFire Private Networks for Manufacturing
- Press Release: MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise
- White Paper: “5G Private Networks for Maritime Use Opportunities for Digital Port Automation ,” Beecham Research
- White Paper: “The Importance of Spectrum Liberalization for Private 5G Networks,” ABI Research
About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005742/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom